Mesigyna® once-a-month combined injectable contraceptive: Experience in Latin America

Contraception

Volumn 61, Issue 5, 2000, Pages 309-316

  Bassol, S ^a   Cravioto, M C ^b   Durand, M ^b   Bailon, R ^c   Carranza, S ^c   Fugarolas, J ^c   Gaona, R ^c   Parada, L M ^c   Celis, C ^c   Santoyo, S ^c   Garza Flores, J ^d   Vazquez, L ^d   Lopez, C ^e   Gurucharri, C ^f   Novelli, J ^g   Carneiro De Oliveira, H ^h   Mendez, J ⁱ   De Andrade, M E ^j   De Mello, N R ^k   De Melo, K ⁱ   Chada, E ⁱ   Yassle, M E ^l   Castaneda A ^m   Gomez, P ⁿ   Arboleda, C ^o   Trujillo, L ^p   Bucheli, R ^q   Hidalgo, I ^r   Olavide, R ^s   Parejarios, J ^t   Succar, J ^t   Reyes Marquez, R ^u   Albrecht, G ^u   more..

^a Ctro de Invest Biomedica Univ   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d DF   (Mexico)

^e Inst Modelo Ginecol Y O   (Argentina)

^f Hospital Bernardino Rivadavia   (Argentina)

^g Hospital Frances ^*  (Argentina)

^h HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

ⁱ S Casa de Misericordia de Sao Paulo ^*  (Brazil)

^j Ctro Reprod Humana e Fertilizacao   (Brazil)

^k Hosp Das Clinicas Fac Med U   (Brazil)

^l UNIVERSITY OF SÃO PAULO   (Brazil)

^m Research Department   (Colombia)

ⁿ Inst Matern Inf   (Colombia)

^o Clinica Seguro Social   (Colombia)

^p Hospital General de Medellin Luz Castro de Gutierrez ESE   (Colombia)

^q Clinica Privada de Quito   (Ecuador)

^r Clinica Privada de Guayaquil   (Ecuador)

^s Hospital Arzobispo   (Ecuador)

^t Hospital Rosalia   (Ecuador)

^u Ctro Estrategico Canada L   (Mexico)

more..

Author keywords

Menstrual bleeding; Mesigyna; Once a month injectable contraceptive

Indexed keywords

ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; INJECTABLE CONTRACEPTIVE AGENT; CONTRACEPTIVE AGENT; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN; HORMONE; NORETHISTERONE; NORETHISTERONE ENANTATE;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; WEIGHT GAIN; ADOLESCENT; BIOLOGY; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CLINICAL RESEARCH; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS; DEVELOPING COUNTRY; DISEASES; DRUG COMBINATION; ENDOCRINE SYSTEM; FAMILY PLANNING; HEALTH; INJECTABLES; INJECTION; MENSTRUATION; METHODOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PHYSIOLOGY; PREGNANCY; PUBLIC HEALTH; REPRODUCTION; RESEARCH REPORT; SAFETY; SOUTH AND CENTRAL AMERICA; UTERUS BLEEDING;

BIOLOGY; BLEEDING; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS; DEVELOPING COUNTRIES; DISEASES; ENDOCRINE SYSTEM; ESTRADIOL; ESTROGENS; FAMILY PLANNING; HEALTH; HORMONES; INJECTABLES; LATIN AMERICA; MENSTRUATION; NORETHINDRONE; NORETHINDRONE ENANTHATE; PHYSIOLOGY; PUBLIC HEALTH; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; SAFETY; SIGNS AND SYMPTOMS;

ADOLESCENT; ADULT; AMENORRHEA; BLOOD PRESSURE; CONTRACEPTIVE AGENTS, FEMALE; DRUG COMBINATIONS; ESTRADIOL; FEMALE; HUMANS; INJECTIONS; LATIN AMERICA; NORETHINDRONE; PREGNANCY; UTERINE HEMORRHAGE; WEIGHT GAIN;

EID: 0033623805     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00109-8     Document Type: Article

References (19)

1. International Federation of Family Planning. Injectable contraception declaration. 1999;1:l.
2. Trussell J. Vaughan B. Contraceptive failure, method related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72.
3. Djerassi C. The politics of contraception, Vols 1 and 2. California: Stanford Alumni Association, 1970.
4. Gray R.H. Patterns of bleeding associated with the use of steroid contraceptives. In: Diczfalusy E, Fraser IS, Webb FTG, eds. Endometrial Bleeding and Steroidal Contraception. Bath: Pitman Press. 1980;14-44.
5. Facts about injectable contraceptives memorandum from WHO meeting . Bull WHO. 60:1982;199-210.
6. Hall PE. Long-acting injectable formulations. In: Diczfalusy E, Bygdeman M, eds. Fertility Regulation Today and Tomorrow. New York: Serono Symposia Publications, Raven Press, 1987;36:119-41.
7. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction.Task Force on Long-acting Systemic Agents for Fetility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. 1. Contraceptive efficacy and side effects. Contraception 1988,37:1-20.
8. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns. Contraception 1989;40:531-51.
9. Koatsawang S. Once-a-month injectable contraceptives efficacy and reasons for discontinuation . Contraception. 49:1994;387-398.
10. Sang G.W., Shao Q.X., Ge Rs, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. 1. Contraceptive efficacy and side effects. Contraception. 51:1995;167-183.
11. Kesserü E.V., Aydinlik S., Etchepareborda J.J., Kaufman J. A multicentred, two-year, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive. Contraception. 44:1991;589-598.
12. Newton J.R., d'Arcangues C., Hall P.E. Once-a-month combined injectable contraceptives. J Obstet Gynecol. 14:1994;2-34.
13. Aydinlik S. Open multicenter phase III study with once-a-month injectable contraceptive Mesigyna for a duration of three years. Final results Schering Pharma Research Report No. A357, 1993.
14. Makuch R.W., Simon R.M. Sample size requirements for evaluating a conservative therapy. Can Treat Rep. 62:1978;1037-1040.
15. Farley T.M.M. Life table methods for contraceptive research. Statis Med. 5:1986;475-489.
16. Word Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final Report. Contraception 1983;28:1-20.
17. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three monthly at 100 mg or 150 mg. I. Contraceptive efficacy and side effects. Contraception 1986;34:223-35.
18. Sang G.W., Shao Q.X., Ge Rs, et al. A multicentred pahse III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception. 51:1995;185-192.
19. Fraser I.S. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. Contraception. 49:1994;399-420.